Mesoblast Reports Positive 24 Month Results in Phase 2 Trial for Chronic Low Back Pain and Initiation of Phase 3 Program at JP Morgan Healthcare Conference
14. Januar 2015 18:13 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Jan. 14, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today presented positive 24-month results from its Phase 2 program for chronic low back...
Japanese Legislation Takes Effect for Expedited Approvals of Regenerative Medical Products
24. November 2014 20:07 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) provided an update to the market on the Pharmaceuticals, Medical Devices and Other...
Mesoblast's Phase 2 Trial Results In Chronic Low Back Pain Presented at North American Spine Society Annual Meeting
12. November 2014 18:36 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Mesoblast's Phase 2 trial results in degenerative disc disease were presented today at the North American Spine Society (NASS)...
Mesoblast Partner JCR Pharmaceuticals Files for Marketing Approval of the First Allogeneic Stem Cell Product in Japan
30. September 2014 20:17 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported that its Japanese partner, JCR...
Mesoblast Unveils Path to Bring Its Key Products to Market
25. August 2014 20:27 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 25, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today reported 2014 financial results and unveiled its...
Pharmaceutical Executive Joins Mesoblast As Chief Financial Officer
24. August 2014 21:16 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 24, 2014 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the appointment of pharmaceutical executive Mr Paul Hodgkinson as...
National Institutes of Health and Mesoblast Enter Into Agreement for 120-Patient Trial In End-Stage Heart Failure
06. August 2014 20:57 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced the signing of an agreement with the United...
Improved Outcomes Using Mesoblast Cells in End-Stage Heart Failure
24. Juni 2014 21:19 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 24, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX: MSB, USOTC: MBLTY) today announced that trial results evaluating a low dose...
Type 2 Diabetes Trial Results Presented by Study Investigators at American Diabetes Association Annual Meeting
18. Juni 2014 23:19 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 18, 2014 (GLOBE NEWSWIRE) -- Results from the Phase 2 trial of Mesoblast's proprietary adult stem cells in type 2 diabetes patients have been presented by Jay...
Mesoblast Accelerates Plans For Commercialization Manufacturing Operations In Singapore
27. Mai 2014 23:10 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, May 27, 2014 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that it is bringing forward plans for its...